Is a peptide isolated from alpha B-crystallin a novel and potent inhibitor of platelet aggregation via dual prevention of PAR-1 and GPIb/V/IX?
Our results provide the basis for a potential new aspect of antiplatelet compound for the therapy of thrombosis and cardiovascular disease.
Our results suggest that sumoylation participates in regulation of STAT1 responses by modulating DNA-binding properties of STAT1.